New Amsterdam Pharma
Louise Kooij joined NewAmsterdam Pharma as of May 2020 as CFO. Before 2016 she worked in different roles with growing responsibility in Finance and in Business. From 2018 till 2020 she was Head of the Rare Disease unit in Central and Eastern Europe, and from 2016 till 2018 she was responsible for leading the Business Operations Europe team. Before 2016 she worked in different roles with growing responsibility in Finance, with her last role in Boston as Vice President Business Control and Analysis (Global scope).
Louise has more than 25 years of professional experience, of which 18 years in Sanofi Genzyme. Prior to Sanofi Genzyme, Louise worked as consultant and auditor at PriceWaterhouseCoopers and also as Product Group Accountant at Hagemeyer N.V. Louise was involved with major projects, like the integration of Genzyme into Sanofi, reorganizations and acquisitions. Louise earned her Master degree from Nyenrode Business University and her auditing degree from Hogeschool Markus Verbeek.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.